Skip to main content
Fig. 6 | Cancer Cell International

Fig. 6

From: The troglitazone derivative EP13 disrupts energy metabolism through respiratory chain complex I inhibition in breast cancer cells and potentiates the antiproliferative effect of glycolysis inhibitors

Fig. 6

EP13 increases the extracellular acidification rate, glucose consumption and lactate production in MDA-MB-231 and MCF-7 cells. MDA-MB-231 (a, c, d, e) and MCF-7 (b, f, g, h) cells were treated for 4 h (a, b, c, f) or 24 h (d, e, g, h) with vehicle or EP13 (6 μM). The extracellular acidification rate (ECAR) (a, b) was measured using XFe24 Seahorse. At the indicated times, the following drugs were injected: Glc (D-glucose; 10 mM), oligomycin A (Oli; 1 µM) and 2DG (2-deoxyglucose 100 mM). The results are depicted as the mean ± S.D. (at least n = 3 wells per group). Glucose (c, d, f, g) and lactate (e, h) concentrations (g/L) were measured in culture medium and normalized relative to cell numbers. The results are depicted as the mean ± SEM of at least three independent measurements. Significant differences from control cells are indicated (*, p < 0.5; ***, p < 0.001)

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us